Previous close | 125.78 |
Open | 126.71 |
Bid | 126.91 x 800 |
Ask | 127.40 x 800 |
Day's range | 126.22 - 128.08 |
52-week range | 99.14 - 133.10 |
Volume | |
Avg. volume | 8,327,698 |
Market cap | 321.543B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | 906.71 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.08 (2.43%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).
BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
RAHWAY, N.J., April 01, 2024--Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25